Poolbeg Pharma 预防严重癌症治疗副作用的药物获得 FDA 孤儿药称号，增加了股票。 Poolbeg Pharma's drug to prevent a severe cancer treatment side effect gets FDA orphan designation, boosting stock.

Poolbeg Pharma的药物POLB 001已经获得FDA指定为孤儿的药物,以防止Cytokine释放综合症(CRS),这是癌症免疫疗法严重影响70%以上的病人的一种副作用。 Poolbeg Pharma's drug, POLB 001, has received FDA orphan drug designation to prevent Cytokine Release Syndrome (CRS), a severe side effect of cancer immunotherapy affecting over 70% of patients. 这一指定支持罕见疾病治疗的发展,提供金融和市场独家经营的好处。 This designation supports rare disease treatment development, offering financial and market exclusivity benefits. POLB 001正在第2a阶段进行试验,预计今年将有第一批病人服用。 POLB 001 is in phase 2a trials with first patients expected to be dosed this year. 普尔贝格制药公司的股份在新闻上上升了11%。 Shares of Poolbeg Pharma rose 11% on the news.